Chorobotwórczość MRSA dla ludzi i zwierząt

• Autorzy: Banaszkiewicz T. , Krukowski H.

Warianty tytułu

EN

Pathogenicity of MRSA for humans and animals

• Języki publikacji: PL

Abstrakty

EN

The first meticillin-resistant strains of Staphylococcus aureus (MRSA) emerged in the early 1960s after the introduction β-lactamases, semi-synthetic penicillins, such as methicillin. For nearly 30 years the incidence was confined to the hospital environment (hospital-associated MRSA, HA-MRSA), which have a selective advantage over strains of S. aureus sensitive to methicillin (meticillin-susceptible Staphylococcus aureus, MSSA). CA-MRSA strains, as well as hospital strains, are capable of inducing a variety of infections; they are frequently responsible for the initial infection of the skin and soft tissues as well as necrotizing pneumonia. The factors that predispose the occurrence of MRSA are: diabetes mellitus, intravenous drug abuse, chronic hemodialysis, the colonization of the skin lesions, specific immunotherapy, neutropenia, increased IgE level, hemodialysis, surgical wound infections, stays in hospitals and nursing homes. The first reports of MRSA occurring in cattle took place in Belgium in 1972. MRSA strains have also been identified in horses, pigs, dogs, poultry and turtles. The common coexistence of VRE and MRSA can lead to the formation of MDR (multidrug resistant) strains of S. aureus. The emergence of multidrug-resistant strains is a major problem for MRSA eradication, and therefore it is necessary to discover antibacterial substances reducing the activity of the pathogens.

Słowa kluczowe

PL

Staphylococcus aureus; szczepy metycylinooporne; gronkowce oporne na metycyline; chorobotworczosc; zwalczanie; czlowiek; zwierzeta; zagrozenia zdrowia

• Wydawca: -
• Czasopismo: Medycyna Weterynaryjna
• Rocznik: 2014
• Tom: 70
• Numer: 03
• Opis fizyczny: s.151-156,bibliogr.

Twórcy

autor

Banaszkiewicz T.

• Katedra Higieny Zwierząt i Środowiska, Wydział Biologii i Hodowli Zwierząt, Uniwersytet Przyrodniczy w Lublinie, ul.Akademicka 13, 20-950 Lublin

autor

Krukowski H.

• Katedra Higieny Zwierząt i Środowiska, Wydział Biologii i Hodowli Zwierząt, Uniwersytet Przyrodniczy w Lublinie, ul.Akademicka 13, 20-950 Lublin

Bibliografia

• 1. Abudu L., Blair I., Fraise A., Cheng K. K.: Methicillin-resistant Staphylococcus aureus (MRSA): a community-based prevalence survey. Epidemiol. Infect. 2001, 126, 351-356.
• 2. Bohlius J., Herbst C., Reiser M., Schwarzer G., Engert A.: Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane database of systematic reviews 2008, (4), CD003189.
• 3. Brook I.: The Increased risk of community-acquired methicillin-resistant Staphylococcus aureus in neck infections in young children. Curr. Infect. Dis. Rep. 2012, 14, 119-120.
• 4. Cea-Pereiro J. C., Garcia-Meijide J., Mera-Varela A., Gomez-Reino J. J.: A comparison between septic bursitis caused by Staphylococcus aureus and those caused by other organisms. Clin. Rheumatol. 2001, 20, 10-14.
• 5. Chambers H., DeLeo F. R.: Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat. Rev. Microbiol. 2009, 7, 629-641.
• 6. Chang S., Suvert D. M., Hageman J. C., Boulton M. L., Tenover F. C., Pouch Downes F.: Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N. Engl. J. Med. 2003, 348, 1342-1347.
• 7. Chiang F. Y., Climo M.: Staphylococcus aureus carriage and health care-acquired infection. Curr. Infect. Dis. Rep. 2002, 4, 498-504.
• 8. Colacite J., Scoaris D., Yamada-Ogatta S., Ueda-Nakamura T., Nakamura C., Dias del Filho B.: Pathogenic potential of Staphylococcus aureus strains isolated from various origins. Ann. Microbiol. 2011, 61, 639-647.
• 9. Cox R. A., Conquest C.: Strategies for the management of healthcare staff colonized with epidemic methicillin-resistant Staphylococcus aureus. J. Hosp. Infect. 1997, 35, 117-127.
• 10. Cruciani M., Gatti G., Lazzarini L., Furlan G., Broccali G., Malena M., Franchini C., Concia E.: Penetration of vancomycin into human lung tissue. J. Antimicrob. Chemother. 1996, 38, 865-869.
• 11. Cuny C., Friedrich A., Kozytska S., Layer F., Nubel U., Ohlsen K., Strommenger B., Walther B., Wieler L., Witte W.: Emergence of methicillin-resistant Staphylococcus aureus (MRSA) indifferent animal species. Int. J. Med. Microbiol. 2010, 300, 109-117.
• 12. Duggal P., Naseri I., Sobol S. E.: The increased risk of community acquired methicillin-resistant Staphylococcus aureus neck abscesses in young children. The Laryngoscope 2011, 121, 51-55.
• 13. Eliopoulos G. M.: Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin. Infect. Dis. 2003, 36, 473-481.
• 14. El-Jakee J., Nagwa A. S., Bakry M., Zouelfakar S., Elgabry E., Gad El-Said W. A.: Characteristics of Staphylococcus aureus strains isolated from human and animal sources. American-Eurasian J. Agric.&Environ. Sci. 2008, 4, 221-229.
• 15. Flemming K., Ackermann G.: Prevalence of enterotoxin producing Staphylococcus aureus in stools of patients with nosocomial diarrhea. Infection 2007, 35, 356-358.
• 16. Fluit A. C., Verhoef J., Schmitz F. J.: European SENTRY Participants. Frequency of isolation and antimicrobial resistance of Gram-negative and Gram-positive bacteria from patients in intensive care units of 25 European university hospitals participating in the European arm of the SENTRY Antimicrobial Surveillance Program 1997-1998. Eur. J. Clin. Microbiol. Infect. Dis. 2001, 20, 617-625.
• 17. Gemmell C. G.: Glycopeptide resistance in Staphylococcus aureus: is it a real threat? J. Infect. Chemother. 2004,10, 69-75.
• 18. Gillet Y., Issartel B., Vanhems P., Fournet J. C., Lina G., Bes M., Vandenesch F., Piémont Y., Brousse N., Floret D., Etienne J.: Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 2002, 359, 753-759.
• 19. Guimarães M. C., Amaral L. G., Rangel L. B., Silva I. V., Matta C. G., Matta M. F.: Growth inhibition of Staphylococcus aureus by chicken egg yolk antibodies. Arch. Immunol. Ther. Exp. (Warsz). 2009, 57, 377-382.
• 20. Gupta R., Prasad Y.: Efficacy of polyvalent bacteriophage p-27/hp to control multidrug resistant Staphylococcus aureus associated with human infections. Curr. Microbiol. 2011, 62, 255-260.
• 21. Hamilton-Miller J. M.: Vancomycin-resistant Staphylococcus aureus: a real and present danger? Infection 2002, 30, 118-124.
• 22. Herold B. C., Immergluck L. C., Maranan M. C., Lauderdale D. S., Gaskin R. E., Vavra S. B., Leitch C. D., Daum R. S.: Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 1998, 279, 593-598.
• 23. Hoeger P. H., Lenz W., Boutonnier A., Fournier J. M.: Staphylococcal skin colonization in children with atopic dermatitis: prevalence, persistence, and transmission of toxigenic and nontoxigenic strains. J. Infect. Dis. 165, 1992, 1064-1068.
• 24. Hyun-Jung K., Se-Wook O.: Performance comparison of 5 selective media used to detect Staphylococcus aureus in foods. Food. Sci. Biotechnol. 2010, 19, 1097-1101.
• 25. Iwase T., Uehara Y., Shinji H., Tajima A., Seo H., Takada K., Agata T., Mizunoe Y.: Staphylococcus epidermidis Esp inhibits Staphylococcus aureus biofilm formation and nasal colonization. Nature 2010, 465, 346-349.
• 26. Klein M., Krönke M., Krut O.: Expression of lysostaphin in HeLa cells protects from host cell killing by intracellular Staphylococcus aureus. Med. Microbiol. Immunol. 2006, 195, 3, 159-163.
• 27. Kos M. I., Stenz L., François P., Guyot J. P., Schrenzel J.: Immuno-detection of Staphylococcus aureus biofilm on a cochlear implant. Infection 2009, 37, 450-454.
• 28. Liu C. I., Liu G. Y., Song Y., Yin F., Hensler M. E., Jeng W. Y., Nizet V., Wang A. H., Oldfield E.: A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus virulence. Science 2008, 319 (5868), 1391-1394.
• 29. Manders S. M.: Toxin-mediated streptococcal and staphylococcal disease. J. Am. Acad. Dermatol. 1998, 39, 383-398.
• 30. Międzobrodzki J., Kaszycki P., Bialecka A., Kasprowicz A.: Proteolytic activity of Staphylococcus aureus strains isolated from the colonized skin of patients with acute-phase atopic dermatitis. Eur. J. Clin. Microbiol. Infect. Dis. 2002, 21, 269-276.
• 31. Miller M., Cespedes C., Vavagiakis P., Klein R. S., Lowy F. D.: Staphylococcus aureus colonization in a community sample of HIV-infected and HIV-uninfected drug users. Eur. J. Clin. Microbiol. Infect. Dis. 2003, 22, 463-469.
• 32. Moran G. J., Krishnadasan A., Gorwitz R. J., Fosheim G. E., McDougal L. K., Carey R. B., Talan D. A.: Methicillin-resistant S. aureus infections among patients in the emergency department. N. Engl. J. Med. 2006, 355, 666-674.
• 33. Morgan M.: Treatment of MRSA soft tissue infections: An overview. Injury 2011, 42, 11-17.
• 34. Nakae T., Hirayama F., Hashimoto M.: Neutralizing activity of human immunoglobulin preparation against toxic shock syndrome toxin-1 (in Japanese). Kansenshogaku Zasshi 2002, 76, 195-202.
• 35. Oktavia Salasia S. I., Khusnan Z., Lammler C., Zschock M.: Comparative studies on phenol-and genotypic properties of Staphylococcus aureus isolated from bovine subclinical mastitis in central Java in Indinesia and Hesse in Germany. J. Vet. Sci. 2004, 5, 103-109.
• 36. Onorato M., Borucki M., Baillargeon G., Paar D. P., Freeman D. H., Cole C. P., Mayhall C. G.: Risk factors for colonization or infection due to methicillin-resistant Staphylococcus aureus in HIV-positive patients: a retrospective case-control study. Infect. Control. Hosp. Epidemiol. 1999, 20, 26-30.
• 37. Otto M.: Staphylococcal biofilms. Curr. Top. Microbiol. Immunol. 2008, 322, 207-228.
• 38. Park B., Liu G. Y.: Targeting the host-pathogen interface for treatment of Staphylococcus aureus infection. Semin. Immunopathol. 2012, 34, 299-315.
• 39. Peacock S. J., de Silva I., Lowy F. D.: What determines nasal carriage of Staphylococcus aureus? Trends in Microbiology 2001, 9, 605-610.
• 40. Polgreen P. M., Herwaldt L. A.: Staphylococcus aureus colonization and nosocomial infections: implications for prevention. Curr. Infect. Dis. Rep. 2004, 6, 435-441.
• 41. Price M. F., Carlini M., Houston S., Gentry L. O.: Prevalence of nasal colonization with methicillin-resistant Staphylococcus aureus in selected patient populations. Infect. Control. Hosp. Epidemiol. 2000, 21, 603-605.
• 42. Que Y. A., Moreillon P. i wsp.: Fibrinogen and fibronectin binding cooperate for valve infection and invasion in Staphylococcus aureus experimental endocarditis. J. Exp. Med. 2005, 201, 1627-1635.
• 43. Raju S., Oli A. K., Patil S. A., Chandrakanth K. R.: Prevalence of multidrug-resistant Staphylococcus aureus in diabetics clinical samples. World J. Microbiol. Biotechnol. 2010, 26, 171-176.
• 44. Rigby K. M., DeLeo F. R.: Neutrophils in innate host defense against Staphylococcus aureus infections. Semin. Immunopathol. 2012, 34, 237-259.
• 45. Saini V., McClure J. T., Léger D., Keefe G. P., Scholl D. T., Morck D. W., Barkema H. W.: Antimicrobial resistance profiles of common mastitis pathogens on Canadian dairy farms. J. Dairy Sci. 2012, 95, 4319-4332.
• 46. Schlievert P. M., Strandberg K. L., Lin Y. C., Peterson M. L., Leung D. Y.: Secreted virulence factor comparison between methicillin-resistant and methicillin-sensitive Staphylococcus aureus, and its relevance to atopic dermatitis. J. Allergy. Clin. Immunol. 2010, 125, 39-49.
• 47. Sissolak D., Geusau A., Heinze G., Witte W., Rotter M. L.: Risk factors for nasal carriage of Staphylococcus aureus in infectious disease patients, including patients infected with HIV, and molecular typing of colonizing strains. Eur. J. Clin. Microbiol. Infect. Dis. 2002, 21, 88-96.
• 48. Spellberg B., Ibrahim A. S., Yeaman M. R., Lin L., Fu Y., Avanesian V., Bayer A. S., Filler S. G., Lipke P., Otoo H., Edwards J. E.: The antifungal vaccine derived from the recombinant N terminus of Als3p protects mice against the bacterium Staphylococcus aureus. Infect Immun. 2008, 76, 4574-4580.
• 49. Tavakol M., Riekerink R. G., Sampimon O. C., van Wamel W. J., van Belkum A., Lam T. J.: Bovine-associated MRSA ST398 in The Netherlands. Acta.Vet. Scand. 2012, 54, 28.
• 50. Tristan A., Ferry T., Durand G., Dauwalder O.: Virulence determinants in community and hospital meticillin-resistant Staphylococcus aureus. J. Hosp. Infect. 2007, 65(S2), 105-109.
• 51. Tsao S. M., Hsu C. C., Yin M. C.: Methicillin-resistant Staphylococcus aureus infection in diabetic mice enhanced inflammation and coagulation. J. Med. Microbiol. 2006, 55, 379-385.
• 52. Tseng M. H., Lin W. J., Teng C. S., Wang C. C.: Primary sternal osteomyelitis due to community-associated methicillin-resistant Staphylococcus aureus: case report and literature review. Eur. J. Pediatr. 2004, 163, 651-653.
• 53. Walencka E., Sadowska B., Różalska S., Hryniewicz W., Różalska B.: Lysostaphin as a potential therapeutic agent for staphylococcal biofilm eradication. Pol. J. Microbiol. 2005, 54, 191-200.
• 54. Weems J. J., Beck L. B.: Nasal carriage of Staphylococcus aureus as a risk factor for skin and soft tissue infections. Curr. Infect. Dis. Rep. 2002, 4, 420-425.
• 55. Yanagisawa C., Hanaki H., Natae T., Sunakawa K.: Neutralization of staphylococcal exotoxins in vitro by human-origin intravenous immunoglobulin. J. Infect. Chemother. 2007, 13, 368-372.